IB 
Union Calendar No. 277 
117TH CONGRESS 
2D SESSION 
H. R. 5585 
[Report No. 117–365] 
To establish the Advanced Research Projects Agency-Health, and for other 
purposes. 
IN THE HOUSE OF REPRESENTATIVES 
OCTOBER 15, 2021 
Ms. ESHOO introduced the following bill; which was referred to the Committee 
on Energy and Commerce 
JUNE 13, 2022 
Additional sponsors: Ms. LOFGREN, Ms. ROYBAL-ALLARD, Mr. THOMPSON of 
California, Mr. HUFFMAN, Mr. COSTA, Mr. SUOZZI, Ms. JOHNSON of 
Texas, Mr. MICHAEL F. DOYLE of Pennsylvania, Ms. WASSERMAN 
SCHULTZ, Mr. MCGOVERN, Mr. CARTWRIGHT, Mrs. FLETCHER, Mr. 
CA´RDENAS, Ms. CRAIG, Mrs. TRAHAN, Mr. PASCRELL, Mr. COURTNEY, 
Mr. PERLMUTTER, Ms. ROSS, Mr. MCNERNEY, Mrs. NAPOLITANO, Mr. 
PETERS, Ms. BARRAGA´N, Mr. LEVIN of California, Mr. TONKO, Ms. 
SCHRIER, Ms. BLUNT
ROCHESTER, Mr. KHANNA, Ms. CHU, Mr. 
DESAULNIER, Mr. SCHIFF, Ms. SPEIER, Mr. AGUILAR, Mr. TRONE, Ms. 
MCCOLLUM, Mr. SCHRADER, Ms. JACOBS of California, Mr. QUIGLEY, 
Mr. MOULTON, Mr. WELCH, Mr. RUSH, Ms. SCHAKOWSKY, Ms. KUSTER, 
Ms. KELLY of Illinois, Mrs. DINGELL, Ms. MATSUI, Ms. CASTOR of Flor-
ida, Mr. O’HALLERAN, Ms. DEGETTE, Mr. UPTON, Ms. SEWELL, Mr. 
SARBANES, Ms. CLARKE of New York, Mr. MORELLE, Mr. GRIJALVA, 
Mr. NADLER, Mr. MCEACHIN, Mr. SOTO, Mr. CARBAJAL, Mr. BISHOP of 
Georgia, Mr. FITZPATRICK, Mr. LAWSON of Florida, Mr. BURGESS, Mr. 
COHEN, Ms. WILLIAMS of Georgia, and Ms. BROWN of Ohio 
JUNE 13, 2022 
Reported with an amendment, committed to the Committee of the Whole 
House on the State of the Union, and ordered to be printed 
[Strike out all after the enacting clause and insert the part printed in italic] 
[For text of introduced bill, see copy of bill as introduced on October 15, 2021] 
VerDate Sep 11 2014 
01:08 Jun 14, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6652
E:\BILLS\H5585.RH
H5585
kjohnson on DSK79L0C42PROD with BILLS
A BILL 
To establish the Advanced Research Projects Agency-Health, 
and for other purposes. 
VerDate Sep 11 2014 
01:08 Jun 14, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6652
E:\BILLS\H5585.RH
H5585
kjohnson on DSK79L0C42PROD with BILLS
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Advanced Research 
Projects Agency–Health Act’’ or the ‘‘ARPA–H Act’’. 
SEC. 2. ADVANCED RESEARCH PROJECTS AGENCY–HEALTH. 
Title IV of the Public Health Service Act (42 U.S.C. 
281 et seq.) is amended by adding at the end the following: 
‘‘PART J—ADVANCED RESEARCH PROJECTS 
AGENCY–HEALTH 
‘‘SEC. 499A. ADVANCED RESEARCH PROJECTS AGENCY– 
HEALTH. 
‘‘(a) ESTABLISHMENT.—There is established, as an 
independent operating division within the Department of 
Health and Human Services, the Advanced Research 
Projects Agency–Health (in this part referred to as ‘ARPA– 
H’). Not later than 180 days after the date of enactment 
of this part, the Secretary shall transfer all functions, per-
sonnel, missions, activities, authorities, and funds of the 
Advanced Research Projects Agency for Health within the 
National Institutes of Health, as in existence on the date 
of enactment of this part, to ARPA–H established by the 
preceding sentence. 
‘‘(b) GOALS AND METHODS.— 
VerDate Sep 11 2014 
01:08 Jun 14, 2022
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6203
E:\BILLS\H5585.RH
H5585
kjohnson on DSK79L0C42PROD with BILLS
‘‘(1) GOALS.—The goals of ARPA–H shall be 
to— 
‘‘(A) foster the development of new, break-
through capabilities, technologies, systems, and 
platforms to accelerate innovations in health and 
medicine that are not being met by Federal pro-
grams or private entities; 
‘‘(B) 
revolutionize 
detection, 
diagnosis, 
mitigation, prevention, treatment, and curing of 
serious diseases and medical conditions through 
the development of transformative health tech-
nologies; 
‘‘(C) promote high-risk, high-reward inno-
vation for the development and translation of 
transformative health technologies; and 
‘‘(D) contribute to ensuring the United 
States maintains— 
‘‘(i) global leadership in science and 
innovation; 
‘‘(ii) the highest quality of life and 
health for its citizens; and 
‘‘(iii) an aggressive agenda for innova-
tions to address global health threats that 
place United States citizens at risk. 
VerDate Sep 11 2014 
01:08 Jun 14, 2022
Jkt 029200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6203
E:\BILLS\H5585.RH
H5585
kjohnson on DSK79L0C42PROD with BILLS
‘‘(2) METHODS.—ARPA–H shall achieve the 
goals specified in paragraph (1) by— 
‘‘(A) discovering, identifying, and pro-
moting 
revolutionary 
advances 
in 
health 
sciences; 
‘‘(B) translating scientific discoveries into 
transformative health technologies; 
‘‘(C) providing resources and support to 
create platform capabilities that draw on mul-
tiple disciplines; 
‘‘(D) using researchers in a wide range of 
disciplines, including the life sciences, the phys-
ical sciences, engineering, and the computational 
sciences; 
‘‘(E) delivering advanced proofs of concept 
that demonstrate potentially clinically meaning-
ful advances; 
‘‘(F) developing new capabilities, advanced 
computational tools, predictive models, or ana-
lytical techniques to identify potential targets 
and technological strategies for early disease de-
tection and intervention; 
‘‘(G) accelerating transformational techno-
logical advances in areas with limited technical 
certainty; and 
VerDate Sep 11 2014 
01:08 Jun 14, 2022
Jkt 029200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6203
E:\BILLS\H5585.RH
H5585
kjohnson on DSK79L0C42PROD with BILLS
‘‘(H) prioritizing investments based on such 
considerations as— 
‘‘(i) scientific opportunity and unique-
ness of fit to the strategies and operating 
practices of ARPA–H; 
‘‘(ii) the effect on disease burden, in-
cluding unmet patient need, quality and 
disparity gaps, and the potential to pre-
empt progression of serious disease; and 
‘‘(iii) the effect on the fiscal liability of 
the Federal Government with respect to 
health care and the ability to reduce the cost 
of care through innovation. 
‘‘(c) DIRECTOR.— 
‘‘(1) IN GENERAL.—The President shall appoint 
with the advice and consent of the Senate, a director 
of ARPA–H (in this part referred to as the ‘Direc-
tor’). 
‘‘(2) QUALIFICATIONS.—The Director shall be an 
individual who, by reason of professional background 
and experience, is especially qualified to manage— 
‘‘(A) research and advanced development 
programs; and 
‘‘(B) large-scale, high-risk initiatives with 
respect to health research and technology develop-
VerDate Sep 11 2014 
01:08 Jun 14, 2022
Jkt 029200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6203
E:\BILLS\H5585.RH
H5585
kjohnson on DSK79L0C42PROD with BILLS
ment across multiple sectors, including gener-
ating transformative health technologies and im-
proving health outcomes for patients. 
‘‘(3) RELATIONSHIP TO SECRETARY.—The Direc-
tor shall report directly to the Secretary. 
‘‘(4) DUTIES.—The duties of the Director shall 
include the following: 
‘‘(A) Approve and terminate the projects 
and programs of ARPA–H. 
‘‘(B) Set research and development prior-
ities with respect to the goals specified in sub-
section (b) and manage the budget of ARPA–H. 
‘‘(C) Develop funding criteria and assess the 
success of programs through the establishment of 
technical milestones. 
‘‘(D) Advance the goals under subsection 
(b), through consideration of the advice of the 
ARPA–H Interagency Research Council estab-
lished under subsection (q). 
‘‘(E) Solicit data, as needed, from the Na-
tional Institutes of Health and other relevant en-
tities. 
‘‘(F) Coordinate with the Director of the 
National Institutes of Health to ensure that the 
programs of ARPA–H build on, and are in-
VerDate Sep 11 2014 
01:08 Jun 14, 2022
Jkt 029200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6203
E:\BILLS\H5585.RH
H5585
kjohnson on DSK79L0C42PROD with BILLS
formed by, scientific research supported by the 
National Institutes of Health. 
‘‘(G) Coordinate with the heads of Federal 
agencies and, to the extent practicable, ensure 
that the activities of ARPA–H supplement (and 
do not supplant) the efforts of other Federal 
agencies. 
‘‘(H) Ensure ARPA–H does not provide 
funding for a project unless the program man-
ager determines that the project meets the goals 
described in subsection (b)(1). 
‘‘(5) TERM.—The Director— 
‘‘(A) shall be appointed for a 5-year term; 
and 
‘‘(B) may be reappointed for 1 consecutive 
5-year term. 
‘‘(6) AUTONOMY
OF
AGENCY
REGARDING
REC-
OMMENDATIONS AND TESTIMONY.—No officer or agen-
cy of the United States shall have any authority to 
require the Director or any other officer of ARPA–H 
to submit legislative recommendations, or testimony 
or comments on legislation, to any officer or agency 
of the United States for approval, comments, or re-
view prior to the submission of such recommenda-
tions, testimony, or comments to the Congress, if such 
VerDate Sep 11 2014 
01:08 Jun 14, 2022
Jkt 029200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6203
E:\BILLS\H5585.RH
H5585
kjohnson on DSK79L0C42PROD with BILLS
recommendations, testimony, or comments to the Con-
gress include a statement indicating that the views 
expressed therein are those of the Director or such offi-
cer, and do not necessarily reflect the views of the 
President or another agency. 
‘‘(7) DELEGATION OF AUTHORITY.—The Director 
may delegate to any duly authorized employee, rep-
resentative, or agent any power vested in the Director 
by law, except that the Director may not delegate the 
power to appoint the Deputy Director under para-
graph (8). 
‘‘(8) DEPUTY DIRECTOR.—The Director shall ap-
point a deputy director to serve as the first assistant 
to the office. 
‘‘(d) 
APPLICATION
OF
PAPERWORK
REDUCTION 
ACT.—The Director may waive the requirements of sub-
chapter I of chapter 35 of title 44, United States Code (com-
monly referred to as the ‘Paperwork Reduction Act’) with 
respect to the methods described in subsection (b)(2). 
‘‘(e) PROTECTION OF INFORMATION.—The following 
types of information collected by ARPA–H from recipients 
of financial assistance awards shall be considered commer-
cial and financial information obtained from a person and 
privileged or confidential and not subject to disclosure 
under section 552(b)(4) of title 5, United States Code: 
VerDate Sep 11 2014 
01:08 Jun 14, 2022
Jkt 029200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6203
E:\BILLS\H5585.RH
H5585
kjohnson on DSK79L0C42PROD with BILLS